Câncer Cervical: Acesso Aberto

Abstrato

Colposcopy Directed Cervical Biopsy and Loop Electrosurgical-Excision Procedures

Willy Nelson

Objective: LEEP samples from patients with colposcopy biopsy-proven CIN2 or 3, the goal is to estimate the proportion of patients with CIN1 or less.

Materials and procedures: This study reviewed descriptive charts in the past. Clinical information was obtained from the medical records of women who received a LEEP treatment between 2004 and 2014 and had CIN2 or 3 from a colposcopy biopsy. The gynaecologic pathologist went over each abnormal slide. There were statistical evaluations done.

14 patients out of 210 were dropped from the research as a result. 196 patients met the eligibility requirements, and the data were examined. 32 patients (16.3%) whose previous colposcopy biopsies revealed CIN2 or 3 had CIN1 or less according to LEEP specimens. The only biopsy-based risk factor for CIN1 was CIN2, which was statistically significant.

Results: Of 210 patients, 14 patients were excluded from the study. 196 patients were in eligible criteria and data were analyzed. There were 32 patients (16.3%) with CIN1 or less from LEEP specimens who previously had colposcopy biopsies proven CIN2 or 3. Only CIN2 from biopsy was the statistically significant risk factor of CIN1 or less in LEEP specimens. Odds ratio was 10.45 (95% confidence interval: 3.28–33.33, P < 0.001).

Conclusion: The prevalence of patients with CIN1 or less from LEEP specimens who previously had colposcopy biopsies proven CIN2 or 3 were 16.3%. CIN2 from biopsy was the statistically significant risk factor of CIN1 or less in LEEP specimens.